Mr. Speaker, I rise today in support of H.R. 3, the Stem Cell Research Enhancement Act, legislation I have authored with the distinguished lady from Colorado, Ms. DeGette, to ethically expand the…
Mr. Speaker, I rise today in support of H.R. 3, the Stem Cell Research Enhancement Act, legislation I have authored with the distinguished lady from Colorado, Ms. DeGette, to ethically expand the current Federal embryonic stem cell research policy.
We have a real opportunity to make history, to pass legislation that will jump start research and may lead to treatments and cures for countless diseases, including diabetes, HIV/AIDS, Parkinson's Disease, Alzheimer's, ALS, multiple sclerosis and cancer. There is overwhelming support for this research, with 70 percent of the American people backing it.
There are also 500 universities, medical societies and advocacy groups backing this research, ranging from the American Medical Association and the Academy of Physicians to universities like the University of California and Harvard University and advocacy groups like the Juvenile Diabetes Research Foundation and the Michael J. Fox Foundation.
This research may also provide a better understanding of the biological origins of certain diseases, as well as an opportunity for pharmaceutical testing.
However, this Nation and, more importantly, our scientists are being held back by a policy that is out of date, short-sighted, arbitrary and, most of all, based on politics and not science.
When the decision was made by President Bush in 2001 to allow Federal funding for stem cell research on lines that had already been created, it seemed that a compromise may have been struck. However, the number of lines has shrunk from 78 to 22, and all of the lines have been compromised.
Since that time, over 150 new and improved stem cell lines have been created in the United States and throughout the world. Despite the fact that these lines are much easier for scientists to use and, in some cases, are disease specific, they are off limits to Federal researchers.
Throughout this debate, you will hear many mistruths, and I think it is important to set the stage early about what this bill does and doesn't do. First, you will hear that this bill expands Federal funding. To the contrary, this bill has nothing to do with funding. It has to do with the source of the embryos and the quality of stem cell lines.
Second, you will hear this bill discourages destruction of human life, or that it uses taxpayer dollars to destroy human life. To the contrary, this bill has nothing to do with destroying lives and everything to do with saving lives.
It is important to understand we are only talking about embryos that are going to be thrown away otherwise as medical waste. We support all options for couples, including embryo adoption, but if the couple decides to discard their embryos as medical waste, we would like them to be available to research.
You will hear this legislation will encourage the creation of embryos for the sake of research. Again, not true. Our bill specifically states that the embryos must have been created for the purpose of fertility treatment, and no money may have exchanged hands.
Even worse, you will hear mistruths spread by a physician hired by the pro-life movement. Specifically, he says cures and treatments have been found using adult stem cells for 65 to 72 diseases. However, if you look at the science and not the hype, you will see a scientific research study published by three leading researchers in the Science Magazine this past summer who found that, in truth, the number is 9, far less than 65.
Mr. Speaker, I would like to enter this study into the Record.
Adult Stem Cell Treatments for Diseases?
(By Shane Smith, William Neaves, Steven Teitelbaum)
Opponents of research with embryonic stem (ES) cells often
claim that adult stem cells provide treatments for 65 human
illnesses. The apparent origin of those claims is a list
created by David A. Prentice, an employee of the Family
Research Council who advises U.S. Senator Sam Brownback (R-
KS) and other opponents of ES cell research (1).
Prentice has said, ``Adult stem cells have now helped
patients with at least 65 different human diseases. It's real
help for real patients'' (2). On 4 May, Senator Brownback
stated, ``I ask unanimous consent to have printed in the
Record the listing of 69 different human illnesses being
treated by adult and cord blood stem cells'' (3).
In fact, adult stem cell treatments fully tested in all
required phases of clinical trials and approved by the U.S.
Food and Drug Administration are available to treat only nine
of the conditions on the Prentice list, not 65 [or 72 (4)].
In particular, allogeneic stem cell therapy has proven useful
in treating hematological malignancies and in ameliorating
the side effects of chemotherapy and radiation. Contrary to
what Prentice implies, however, most of his cited treatments
remain unproven and await clinical validation. Other claims,
such as those for Parkinson's or spinal cord injury, are
simply untenable.
The references Prentice cites as the basis for his list
include various case reports, a meeting abstract, a newspaper
article, and anecdotal testimony before a Congressional
committee. A review of those references reveals that Prentice
not only misrepresents existing adult stem cell treatments
but also frequently distorts the nature and content of the
references he cites (5).
For example, to support the inclusion of Parkinson's
disease on his list, Prentice cites Congressional testimony
by a patient (6) and a physician (7), a meeting abstract by
the same physician (8), and two publications that have
nothing to do with stem cell therapy for Parkinson's (9, 10).
In fact, there is currently no FDA-approved adult stem cell
treatment-and no cure of any kind-for Parkinson's disease.
For spinal cord injury, Prentice cites personal opinions
expressed in Congressional testimony by one physician and two
patients (11). There is currently no FDA-approved adult stem
cell treatment or cure for spinal cord injury.
The reference Prentice cites for testicular cancer on his
list does not report patient response to adult stem cell
therapy (12); it simply evaluates different methods of adult
stem cell isolation.
The reference Prentice cites on non-Hodgkin's lymphoma does
not assess the treatment value of adult stem cell
transplantation (13); rather, it describes culture conditions
for the laboratory growth of stem cells from lymphoma
patients.
Prentice's listing of Sandhoff disease, a rare disease that
affects the central nervous system, is based on a layperson's
statement in a newspaper article (14). There is currently no
cure of any kind for Sandhoff disease.
By promoting the falsehood that adult stem cell treatments
are already in general use for 65 diseases and injuries,
Prentice and those who repeat his claims mislead laypeople
and cruelly deceive patients.
References
1. Posted at the Web site of DoNoHarm, The Coalition of
Americans for Research Ethics (accessed 8 May 2006 at http:// www.stemcellresearch.org/facts/treatments.htm).
2. D. Prentice, Christianity Today 49 (no. 10), 71 (17 Oct.
2005) (accessed 8 May 2006 at www.christianitytoday.com/ct/ 2005/010/24.71.html).
3. S. Brownback, ``Stem cells,'' Congressional Record, 4 May
2006 (Senate) (Page S4005-S4006) (accessed 8 May 2006 at
http://frwebgate6.access.gpo.gov/cgi-bin/ waisgate.cgi?WAISdocID=122359256098+2+2+0 &WAI
Saction=retrieve).
4. According the latest version of the list, accessed 12 July
2006.
5. See chart compiling and analyzing Prentice's list of 65
diseases allegedly treated by adult stem cells at the
supplemental data repository available as Supporting Online
Material on Science Online at www.sciencemag.org/cgi/content/ full/1129987/DC1.
6. D. Turner, Testimony before Senator Sam Brownback's
Science, Technology and Space Subcommittee on 14 July 2004
(accessed 8 May 2006 at http://commerce.senate.gov/hearings/ testimony.cfm?id=1268&wit_id=3676).
7. M. Levesque, Testimony before Senator Sam Brownback's
Science, Technology and Space Subcommittee on 14 July 2004
(accessed 8 May 2006 at http://commerce.senate.gov/hearings/ testimony.cfm?id=1268&wit_id=3670).
8. M. Levesque, T. Neuman, Abstract #702, Annual Meeting of
the American Association of Neurological Surgeons, 8 April
2002.
9. S. Gill et al., Nat. Med. 9, 589 (2003).
10. S. Love et al., Nat. Med. 11, 703 (2005).
11. M. Levesque, Testimony before Senator Sam Brownback's
Science, Technology and Space Subcommittee on 14 July 2004
(accessed 8 May 2006 at http://commerce.senate.gov/hearings/ testimony.cfm?id=1268&wit_id=3670); L. Dominguez, Testimony
before Senator Sam Brownback's Science, Technology and Space
Subcommittee on 14 July 2004 (accessed 8 May 2006 at http:// commerce.senate.gov/hearings/ testimony.cfm?id=1268&wit_id=3673); S. Fajt, Testimony before
Senator Sam Brownback's Science, Technology and Space
Subcommittee on 14 July 2004 (accessed 8 May 2006 at http:// commerce.senate.gov/hearings/ testimony.cfm?id=1268&wit_id=3674).
12. K. Hanazawa et al., Int. J. Urol. 7, 77 (2000).
13. M Yao et al., Bone Marrow Transpl. 26, 497 (2000).
14. K Auge, ``Stem cells infuse kin with hope,'' Denver Post,
24 Aug. 2004.
11 May 2006; accepted 13 July 2006.
Published online 13 July 2006; 10.1126/science. 1129987.
Include this information when citing this paper.
Mr. Speaker, I would also like to point out that adult stem cells were discovered in 1960, and embryonic stem cells were only isolated in 1998. And since 1998, there have been great advances in animal models in the areas of diabetes, spinal cord injury and macular degeneration.
Finally, you will hear about the research concerning amniotic fluid stem cells conducted by Dr. Atala at Wake Forest University. While exciting, this is nothing new, nor do these stem cells have the same capacity to divide into all cell types in the body, as embryonic stem cells do. Yet you will hear opponents say they do.
Mr. Speaker, I would like to enter the letter in the Record on that as well.
Wake Forest Institute for
Regenerative Medicine,
Winston-Salem, NC, January 8, 2007.
Hon. Diana DeGette,
Hon. Michael Castle,
House of Representatives, Washington, DC.
Dear Representatives DeGette and Castle: I am writing in
regard to my research that was published in Nature
Biotechnology that found that stem celts obtained from
amniotic fluid have been able to differendate into several
cell types. This research has the potential to open up an
important field of inquiry that could be critically important
to the development of treatments within the field of
regenerative medicine.
I understand that some may be interpreting my research as a
substitute for the need to pursue other forms of regenerative
medicine therapies, such asthose involving embryonic stem
cells. I disagree with that assertion. It is very possible
that research involving embryonic stem cells will have
critical implications for advancing research into amniotic
fluid stem cells. It is essential that National Institute of
Health-funded researchers are able to fully pursue embryonic
stem cell research as a complement to research into other
forms of stem cells.
Your legislation, the Stem Cell Research Enhancement Act of
2007, H.R. 3, would update the current federal embryonic stem
cell policy and allow federally funded researchers to conduct
research on an expanded set of embryonic stem cells within an
ethical framework. I believe this legislation would speed
science in the regenerative medicine field, and I support its
passage.
Sincerely,
Anthony Atala, MD.
Mr. Speaker, I yield 2 minutes to the distinguished gentleman from Connecticut (Mr. Shays).
Mr. Speaker, I yield 1 minute to the distinguished gentleman from Illinois (Mr. Kirk).
(Mr. KIRK asked and was given permission to revise and extend his remarks.)
Mr. Speaker, at this time I yield to the gentlewoman from Illinois (Mrs. Biggert) for a unanimous-consent request.
(Mrs. BIGGERT asked and was given permission to revise and extend her remarks.)
At this time I yield 1\1/2\ minutes to the distinguished gentleman from California (Mr. Bilbray).
Mr. Speaker, at this time I yield myself 1 minute.
Mr. Speaker, I would just like to continue the discussion that the gentlewoman from Colorado had on the IVF process in the clinics. There is a methodology that many people, even perhaps here, have taken advantage of in terms of being able to procreate, and that is going to an in vitro fertilization clinic, and that is done commonly in this country.
Right now, by survey, there are about 400,000 embryos frozen in those clinics around the country. About 2 percent a year are disposed of. That is about 8,000. Why are they disposed of? For a variety of reasons. People may divorce. Perhaps they have children. Who knows what the reasons may be, but they are disposed of. How are they disposed of? How are those 8,000 disposed of? A decision is made by the original creators of that particular embryo and by the physician running the in vitro fertilization clinic that they will be disposed of, and then they are put in as hospital waste; so they are not going to be life. It is only those embryos that would be used in this situation to develop the stem cell lines that we are talking about. It is very important to understand that they are going to be disposed of anyhow as hospital waste or are they going to be used for research.